HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has submitted a supplemental Biologics License Application (sBLA) to the U.S.

Understand how psoriatic arthritis increases heart disease risk through inflammation. Learn management tips for heart health, from lifestyle changes to medication discussions.

Tildrakizumab is an interleukin-23 antagonist approved under the brand name Ilumya for the treatment of plaque psoriasis.

Submission is supported by 24-week results from the Phase 3b APEX study in adults with active psoriatic arthritis treated ...

The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.

The submission is supported by Phase IIIb APEX trial results showing Tremfya reduced symptoms and inhibited structural progression in biologic-naïve patients with active psoriatic arthritis.

Explore the potential of GLP-1 receptor agonists for rheumatoid arthritis. Learn about their safety, benefits, and what to consider before starting these medications.

Self-care methods for psoriatic arthritis (PsA) include staying active with gentle exercises, getting enough sleep, and ...

Immunology products like TREMFYA (used for autoimmune diseases), as well as neuroscience drug SPRAVATO (for depression), also contributed.

Psoriatic Arthritis Through the Lens of a Black Dermatologist Sponsored by Takeda As a Black doctor specializing in psoriatic arthritis (PsA), I have noticed the difficulties in diagnosing and ...

A global comparison of psoriatic arthritis guidelines reveals differences in treatment sequencing and domain-specific strategies, with all emphasizing treat-to-target goals and comorbidity management.

Patients with inflammatory arthritis would benefit from vaccination against herpes zoster, with the Shingrix vaccine showing a crude effectiveness of 50%.